跳至主要内容
临床试验/NL-OMON25974
NL-OMON25974招募中不适用

Evaluating the effect of zolpidem and suvorexant in healthy elderly volunteers on walking (adapt)ability.

CHDR0 个研究点目标入组 18 人开始时间: 待定最近更新:

试验速览

阶段
不适用
状态
招募中
发起方
CHDR
入组人数
18

研究概览

简要总结

.A.

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Male and female subjects aged between 65 years and 80 years (inclusive) at screening.
  • 2. Body mass index (BMI) within the range of 18 to 30 kg/m2 (inclusive) at screening.
  • 3. Systolic blood pressure 100-160 mmHg, diastolic blood pressure 50-95 mmHg, and pulse rate 45-100 bpm(inclusive), measured on either arm, after 5 min in the supine position at screening.
  • 4. Estimated creatinine clearance (using the Cockcroft &Gault formula) =60 mL/min to allow for some reduced renal function in the elderly.
  • 5. Subject has a regular sleep pattern (bedtime between 22:00 and 00:30 and sleep for at least 6 h).

排除标准

  • 1. Hypersensitivity to benzodiazepines and/ or meeting contraindication criteria for zolpidem: myasthenia gravis, sleep apnea syndrome, liver failure, respiratory depression.
  • 2. Hypersensitivity to orexin antagonist and/ or meeting contraindication criteria for suvorexant: narcolepsy.
  • 3. Regular use of sedative/hypnotic drugs.
  • 4. Regular use of walking aids.
  • 5. Recurrent fallers defined as > 3 falls per year.
  • 6. Neurological diseases and/or orthopedic problems interfering with gait function
  • 7. Mini Mental State Examination score < 25 at Screening.
  • 8. Current or previous diagnosis of insomnia-related disorder according to the Diagnostic and Statistical Manual of Mental Disorders version 5 (DSM-5) criteria.
  • 9. Vaccination for SARS-CoV-2 within 4 days of screening and/or dosing with study drug.

研究者

发起方
CHDR

相似试验

Evaluating the effect of zolpidem and suvorexant on... | 临床试验